Astraveus awarded €10.4 million grant by the French government as part of France 2030 investment plan
- Significant endorsement by the French government programme that promotes excellence in research and manufacturing of novel biotherapies
- Advances the Company’s ambitions for its Lakhesys™ platform
- Total company funding now over €30 Million
Paris, France, October 24, 2023 – Astraveus SAS (“Astraveus” or the “Company”), the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, today announces it has been awarded a further €10.4 Million grant by the French government as part of its “Innovation in Biotherapies and Bioproduction” initiative. This initiative promotes excellence in research and manufacturing of novel biotherapies. The funds will be used to advance the development of Astraveus’ Lakhesys ™ platform.
